Helmut
★★★
avatar
Homepage
Vienna, Austria,
2010-08-03 18:38
(5008 d 03:21 ago)

Posting: # 5711
Views: 8,214
 

 EMA: Questions & Answers [BE/BA News]

Dear all,

'Questions & Answers: Positions on specific questions addressed to the EWP therapeutic subgroup on Pharmacokinetics' were updated on 22 July 2010.

Two issues, namely
  • Bioequivalence studies for paroxetine (single dose versus multiple dose studies) and
  • Interpretation of bioequivalence data in relation to both parent and metabolite PK data
were deleted, since they are covered in the new BE-GL.

Other points were updated
  • Requirements for food-interaction studies for modified release formulations
  • Bioequivalence of gastro-resistant preparations (e.g. omeprazole)
  • Bioequivalence studies for generic products containing clopidogrel
or added, namely
  • Acceptance criteria for bioequivalence studies for losartan
  • Bioequivalence assessment of generics for tacrolimus
  • Requirements for demonstration of bioequivalence for ciclosporine generics

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
Jaime_R
★★  

Barcelona,
2010-08-03 19:03
(5008 d 02:55 ago)

@ Helmut
Posting: # 5712
Views: 6,810
 

 Acceptance ranges

Dear Helmut and all,

interesting; now we have the first official statement about some NTIDs!
  • Tacrolimus: 90%-111% for AUC and 80%-125% for Cmax
  • Ciclosporine: 90%-111% for AUC and Cmax (fasting and fed)
Also a clear statement, where widening for Cmax is not acceptable (Clopidogrel, Losartan).

Regards, Jaime
UA Flag
Activity
 Admin contact
22,988 posts in 4,825 threads, 1,661 registered users;
104 visitors (0 registered, 104 guests [including 5 identified bots]).
Forum time: 21:59 CEST (Europe/Vienna)

The only way to comprehend what mathematicians mean by Infinity
is to contemplate the extent of human stupidity.    Voltaire

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5